Painful trigeminal neuropathy associated with anti-Plexin D1 antibody
Citation Manager Formats
Make Comment
See Comments

Article Information
- Received March 24, 2020
- Accepted in final form May 14, 2020
- First Published June 25, 2020.
Author Disclosures
- Takayuki Fujii, MD, PhD,
- Ryo Yamasaki, MD, PhD,
- Yukino Miyachi, MSc,
- Kyoko Iinuma, MSc,
- Yu Hashimoto, MD,
- Noriko Isobe, MD, PhD,
- Takuya Matsushita, MD, PhD and
- Jun-ichi Kira, MD, PhD
- Takayuki Fujii, MD, PhD,
NONE
NONE
(1)Takeda Pharmaceutical Company, speaker honoraria (2)Eisai, speaker honoraria
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
(1) Mitsubishi Tanabe Pharma, (2) Osoegawa Neurology Clinic, (3) Bayer Yakuhin, Ltd., (4) the Japan Blood Products Organization
(1) the Japan Society for the Promotion of Science (JSPS) KAKENHI, grant number 19K17037, principal investigator, 2019-2020
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Ryo Yamasaki, MD, PhD,
NONE
NONE
NONE
Clinical and experimental neuroimmunology, managing editor, since 2016 until now
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Yukino Miyachi, MSc,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Kyoko Iinuma, MSc,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Yu Hashimoto, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Noriko Isobe, MD, PhD,
(1) Commercial, Oxford Health Policy Forum CIC (scientific steering committee member for triMS-online)
NONE
(1) Novartis Pharma, speaker honoraria, (2) Alexion, speaker honoraria, (3) Takeda Pharmaceutical Company, speaker honoraria, (4) Biogen Japan, speaker honoraria, (5) Mitsubishi Tanabe Pharma, speaker honoraria.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
(1) Mitsubishi Tanabe Pharma, (2) Osoegawa Neurology Clinic, (3) Bayer Yakuhin, Ltd., (4) Japan Blood Products Organization.
(1) Grant-in-Aid for Research Activity Start-up (JSPS KAKENHI), 17H06938, Principal Investigator, 2017, and (2) Grant-in-Aid for Scientific Research (C) (JSPS KAKENHI), 18K07529, Principal Investigator, 2018-2021.
NONE
(1) Japan Multiple Sclerosis Society, and (2) Japan Intractable Disease Foundation.
NONE
NONE
NONE
NONE
NONE
NONE
- Takuya Matsushita, MD, PhD and
NONE
NONE
(1) Bayer-Schering Pharma, Speaker honoraria (2) Mitsubishi Tanabe Pharma, Speaker honoraria (3) Biogen, Speaker honoraria, (4) Takeda Pharmaceutical Co. Ltd, Speaker honoraria (5) MSD K.K., Speaker honoraria
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
(1) Grant-in-Aid for Scientific Research (C), Grant-in-Aid for Scientific Research (KAKENHI) of Japan Society for the Promotion of Science, 17889552, Co- investigator, 2017 (2) Grant-in-Aid for Scientific Research (A), Grant-in-Aid for Scientific Research (KAKENHI) of Japan Society for the Promotion of Science, 16805610, Co- investigator, 2016-2017 (3) Grant-in-Aid for Scientific Research (C), Grant-in-Aid for Scientific Research (KAKENHI) of Japan Society for the Promotion of Science, 15571065, Investigator, 2016-2017
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Jun-ichi Kira, MD, PhD
NONE
NONE
JK received speaking fees and/or honoraria from (1) Novartis Pharma, (2) Mitsubishi Tanabe Pharma, (3) Boehringer Ingelheim, (4) Teijin Pharma, (5) the Takeda Pharmaceutical Company, (6) Otsuka Pharmaceutical, (7) Astellas Pharma, (8) Pfizer Japan, and (9) Eisai.
(1) Multiple Sclerosis Journal, Editorial Board Member, 2006-, (2) BMC Medicine, Editorial Board Member, 2010-, (3) Journal of the Neurological Sciences, Editorial Board Member, 2010-, (4) Multiple Sclerosis and Related Disorders, Editorial Board Member, Section Editor, 2011-, (5) PLOS ONE, Editorial Board Member, 2011-, (6) Frontiers in Immunology, Associate Editor, 2017-
NONE
NONE
NONE
(1) Biogen Japan (consultancy, since 2009)
NONE
NONE
NONE
(1) Novartis Pharma, (2) Boehringer Ingelheim, (3) Teijin Pharma, (4) Takeda Pharmaceutical Company, (5) Otsuka Pharmaceutical, (6) Astellas Pharma, (7) Pfizer Japan, (8) Eisai, (9) Dainippon-Sumitomo Pharmaceutical, (10) Tanabe- Mitsubishi Pharmaceutical, (11) Japan Blood Products Organization, (12) Bayer
(1) Grant-in-Aid for Scientific Research on Innovative Areas (MEXT KAKENHI), 25117012, Principal Investigator, 2013-2018, (2) Grant-in-Aid for Scientific Research on Innovative Areas (MEXT KAKENHI), 25117001, Co- investigator, 2013-2018, (3) Grant-in-Aid for Scientific Research on Innovative Areas (MEXT KAKENHI), 15K21729, Co-investigator, 2015-2018, (4) Grant-in-Aid for Challenging Exploratory Research (JSPS KAKENHI), 15K15341, Principal Investigator, 2015-2017, (5) Grant-in-Aid for Scientific Research (C) (JSPS KAKENHI), 15K09343, Co- investigator, 2015-2018, (6) Grant-in-Aid for Scientific Research (C) (JSPS KAKENHI), 16K10727, Co- investigator, 2016-2019, (7) Grant-in-Aid for Scientific Research (A) (JSPS KAKENHI), 16H02657, Principal Investigator, 2016-2019, (8) Grant-in-Aid for Challenging Exploratory Research (JSPS KAKENHI), 17K19663, Principal Investigator, 2017-2019, (9) Grant-in-Aid for Scientific Research (C) (JSPS KAKENHI), 18K07529, Co- investigator, 2018-2021, (10) Grant-in-Aid for Scientific Research (A) (JSPS KAKENHI), 19H01045, Principal Investigator, 2019-2022, (11) Practical Research Project for Rare/Intractable Diseases" from Japan Agency for Medical Research and Development, AMED, Japan, 16ek0109039h0003, Principal Investigator, 2016-2017, (12) Practical Research Project for Rare/Intractable Diseases" from Japan Agency for Medical Research and Development, AMED, Japan, 17ek0109115h0003, Principal Investigator, 2015-2018, (13) Practical Research Project for Rare/Intractable Diseases" from Japan Agency for Medical Research and Development, AMED, Japan, 18ek0109376h0001, Principal Investigator, 2018-2021, (14) Practical Research Project for Rare/Intractable Diseases" from Japan Agency for Medical Research and Development, AMED, Japan, 18ek0109308h0001, Principal Investigator, 2018-2021, (15) Health and Labour Sciences Research Grant on Intractable Diseases from the Ministry of Health, Labour, and Welfare, Japan, H29- Nanchitou(Nan)-Shitei-001, Co-investigator, 2017-2020, (16) Health and Labour Sciences Research Grant on Intractable Diseases from the Ministry of Health, Labour, and Welfare, Japan, H29-Nanchitou(Nan)-Ippan-043, Co- investigator, 2017-2020, (17) Health and Labour Sciences Research Grant on Intractable Diseases from the Ministry of Health, Labour, and Welfare, Japan, H29- Nanchitou(Nan)-Ippan-033, Co-investigator, 2017-2020, (18) Health and Labour Sciences Research Grant on Intractable Diseases from the Ministry of Health, Labour, and Welfare, Japan, H29-Nanchitou(Nan)-Ippan-009, Co- investigator, 2017-2020, (19) Health and Labour Sciences Research Grant on Intractable Diseases from the Ministry of Health, Labour, and Welfare, Japan, H28- Nanchitou(Nan)-Ippan-025, Principal Investigator, 2016- 2019, (20) Health and Labour Sciences Research Grant on Intractable Diseases from the Ministry of Health, Labour, and Welfare, Japan, H28-Nanchitou(Nan)-Ippan-018, Co-investigator, 2016-2019
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- From the Department of Neurological Therapeutics (T.F., N.I.), Neurological Institute, Graduate School of Medical Sciences, Kyushu University, Higashi-ku, Fukuoka; Department of Neurology (R.Y., Y.M., K.I., Y.H., T.M., J.K.), Neurological Institute, Graduate School of Medical Sciences, Kyushu University, Higashi-ku, Fukuoka; Translational Neuroscience Center (J.K.), Graduate School of Medicine, and School of Pharmacy at Fukuoka, International University of Health and Welfare, Ookawa, Fukuoka; and Department of Neurology (J.K.), Brain and Nerve Center, Fukuoka Central Hospital, International University of Health and Welfare, Chuou-ku, Japan.
- Correspondence
Dr. Kira kira{at}neuro.med.kyushu-u.ac.jp
Article usage
Cited By...
Letters: Rapid online correspondence
REQUIREMENTS
If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Dr. Daniel Friedman and Dr. Sharon Chiang
► Watch
Related Articles
- No related articles found.